Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction
ABSTRACT Glucose‐6‐phosphate‐dehydrogenase (G6PD) deficiency is a heterogenous disorder that may lead to severe hemolytic events with the ingestion of fava beans and exposure to certain drugs. We report the first case of a 65‐year‐old male with Crohn's disease who developed a hemolytic crisis l...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Pharmacology Research & Perspectives |
| Online Access: | https://doi.org/10.1002/prp2.70143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849239797710716928 |
|---|---|
| author | Laura Patanè Giuseppe Costantino Marco Muscianisi Clara De Francesco Anna Viola Walter Fries |
| author_facet | Laura Patanè Giuseppe Costantino Marco Muscianisi Clara De Francesco Anna Viola Walter Fries |
| author_sort | Laura Patanè |
| collection | DOAJ |
| description | ABSTRACT Glucose‐6‐phosphate‐dehydrogenase (G6PD) deficiency is a heterogenous disorder that may lead to severe hemolytic events with the ingestion of fava beans and exposure to certain drugs. We report the first case of a 65‐year‐old male with Crohn's disease who developed a hemolytic crisis leading to hospitalization shortly after commencement of upadacitinib. An autoimmune condition was excluded but, as his family history was a positive for G6PD deficiency, very low levels of erythrocyte G6PD were detected. Upadacitinib was immediately discontinued with subsequent resolution of hemolysis. This case highlights the importance of rigorous pharmacological surveillance and suggests the need for further studies to clarify the pathogenetic mechanisms underlying this adverse reaction. |
| format | Article |
| id | doaj-art-2aa22b4ace9347bb8fbd8494befbc158 |
| institution | Kabale University |
| issn | 2052-1707 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pharmacology Research & Perspectives |
| spelling | doaj-art-2aa22b4ace9347bb8fbd8494befbc1582025-08-20T04:00:50ZengWileyPharmacology Research & Perspectives2052-17072025-08-01134n/an/a10.1002/prp2.70143Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug ReactionLaura Patanè0Giuseppe Costantino1Marco Muscianisi2Clara De Francesco3Anna Viola4Walter Fries5IBD‐Unit, Department of Clinical and Experimental Medicine University of Messina Messina ItalyIBD‐Unit, Department of Clinical and Experimental Medicine University of Messina Messina ItalyIBD‐Unit, Department of Clinical and Experimental Medicine University of Messina Messina ItalyIBD‐Unit, Department of Clinical and Experimental Medicine University of Messina Messina ItalyIBD‐Unit, Department of Clinical and Experimental Medicine University of Messina Messina ItalyIBD‐Unit, Department of Clinical and Experimental Medicine University of Messina Messina ItalyABSTRACT Glucose‐6‐phosphate‐dehydrogenase (G6PD) deficiency is a heterogenous disorder that may lead to severe hemolytic events with the ingestion of fava beans and exposure to certain drugs. We report the first case of a 65‐year‐old male with Crohn's disease who developed a hemolytic crisis leading to hospitalization shortly after commencement of upadacitinib. An autoimmune condition was excluded but, as his family history was a positive for G6PD deficiency, very low levels of erythrocyte G6PD were detected. Upadacitinib was immediately discontinued with subsequent resolution of hemolysis. This case highlights the importance of rigorous pharmacological surveillance and suggests the need for further studies to clarify the pathogenetic mechanisms underlying this adverse reaction.https://doi.org/10.1002/prp2.70143 |
| spellingShingle | Laura Patanè Giuseppe Costantino Marco Muscianisi Clara De Francesco Anna Viola Walter Fries Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction Pharmacology Research & Perspectives |
| title | Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction |
| title_full | Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction |
| title_fullStr | Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction |
| title_full_unstemmed | Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction |
| title_short | Upadacitinib‐Induced Hemolysis in a Patient With Glucose‐6‐Phosphate Dehydrogenase Deficiency—A Possible Adverse Drug Reaction |
| title_sort | upadacitinib induced hemolysis in a patient with glucose 6 phosphate dehydrogenase deficiency a possible adverse drug reaction |
| url | https://doi.org/10.1002/prp2.70143 |
| work_keys_str_mv | AT laurapatane upadacitinibinducedhemolysisinapatientwithglucose6phosphatedehydrogenasedeficiencyapossibleadversedrugreaction AT giuseppecostantino upadacitinibinducedhemolysisinapatientwithglucose6phosphatedehydrogenasedeficiencyapossibleadversedrugreaction AT marcomuscianisi upadacitinibinducedhemolysisinapatientwithglucose6phosphatedehydrogenasedeficiencyapossibleadversedrugreaction AT claradefrancesco upadacitinibinducedhemolysisinapatientwithglucose6phosphatedehydrogenasedeficiencyapossibleadversedrugreaction AT annaviola upadacitinibinducedhemolysisinapatientwithglucose6phosphatedehydrogenasedeficiencyapossibleadversedrugreaction AT walterfries upadacitinibinducedhemolysisinapatientwithglucose6phosphatedehydrogenasedeficiencyapossibleadversedrugreaction |